- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05489731
VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer (VIC-1911)
Phase I Clinical Study of VIC-1911 Combined With Osimertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGRF- Mutation
This is a nonrandomized, open phase I dose escalation and extension clinical study designed to evaluate Aurora A inhibitor VIC-1911 tablets in combination with oxitinib in Chinese patients with advanced non-small cell lung cancer The safety, tolerability, pharmacokinetic characteristics and preliminary antitumor efficacy were analyzed.
The entire study included the screening period (28 days prior to initialadministration of the investigational drug) and the treatment period (Cycle) EoT is defined as disease progression or intolerable toxicity or premature withdrawal Out]) and the safety follow-up period (28 days after EoT). During dose increments and expansions, subjects followed Safety assessment, PK blood collection, imaging examination and efficacy assessment were performed during the visit plan. Observation subject The safety, tolerability, and occurrence of DLT until disease progression, occurrence of intolerable toxicity, Death, withdrawal of informed consent, loss of follow-up or termination of the study by the sponsor shall prevail.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: li zhang, professor
- Phone Number: 13902282893
- Email: zhangli6@mail.sysu.edu.cn
Study Locations
-
-
-
Guangdong, China
- Recruiting
- Zhangli
-
Contact:
- li zhang, professor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntarily participate in clinical research, sign written informed consent, and be able to abide by clinical visits and research Relevant procedures;
- Male or female patients aged 18-75 (including boundary value) when signing the informed consent form;
- NSCLC with advanced EGFR mutation positive [exon 19 deletion (19del) and exon 21 L858R (21l858r) point mutation] confirmed by cytology or histology A. only applicable to the dose increasing stage: after receiving the first / second generation EGFR-TKI treatment failure T790M mutation negative or third-generation EGFR-TKI treatment failed, and then received platinum containing dual drug chemotherapy Terminal NSCLC patients after failure; B. only applicable to the expansion phase: (1) queue 1: after the treatment failure of the first / second generation EGFR-TKI NSCLC patients with T790M mutation positive; (2) Cohort 2: NSCLC patients who failed to receive three generations of EGFR-tki treatment;
- According to RECIST 1.1 standard, patients must have a passing shadow Measurable lesions assessed by imaging examination;
- The EC0G score is 0 or 1;
- Estimated survival time ≥ 3 months;
Bone marrow reserve and organ function level within 7 days before administration must meet the following requirements:
- Bone marrow reserve: hemoglobin (HB) ≥ 9.0 g/dl, absolute neutrophil count (ANC)≥ 1.5 × 109/l, platelet (PLT) ≥ 100 × 109/l, opened during the study treatment period Blood transfusion (whole blood, platelets or red blood cells) is prohibited 1 month before the start;
- Coagulation function: international normalized ratio (INR) ≤ 1.5 × Upper normal value (ULN), active Partial prothrombin time (APTT) ≤ 1.5 × ULN;
- Liver function: aspartate aminotransferase (AST) and alanine in the absence of liver metastasis Transaminase (ALT) ≤ 2.5 × ULN; In case of liver metastasis, AST and alt ≤ 5.0 × ULN;Total bilirubin in serum (TBIL) ≤ 1.5 × ULN (patients known to have Gilbert syndrome Only when total bilirubin ≤ 3 × ULN, direct bilirubin ≤ 1.5 × In the case of ULN, it will be Consider);
- Renal function: creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 40 ml/min (according to Cockcroft-Gault formula);
- Cardiac function: left ventricular ejection fraction (LVEF) ≥ 50%; ECG is basically normal,QT interval (QTCF) corrected by fridericia formula: male ≤ 450 ms, female ≤ 470 ms;
- Qualified patients (male and female) with fertility must agree to give drugs during the trial or at the end of the trial Use reliable contraceptive methods (hormone or barrier method or abstinence) with their partners for at least 6 months Etc.); Women of childbearing age (refer to the appendix of the text for the definition) within 7 days before the first use of the investigational drug The pregnancy test must be negative.
Exclusion criteria:
- Known allergy to, or hypersensitivity to, VIC-1911, osimertinib, or any of the excipient ingredients
- Subject has previously discontinued osimertinib due to toxicity or other safety events Interstitial lung disease/non-infectious pneumonia; Symptoms or signs of severe arrhythmia with prolonged QTc interval; Symptomatic congestive heart failure
- Other side effects caused by previous treatment did not alleviate to CTCAE≤ grade 1, alopecia or otherwise
- A history of ocular disease was present, and the patient had occlusion of central or branch retinal arteries or veins with visual acuity Significant decline, or a history of visual impairment due to other retinal diseases as determined by an ophthalmologist or Performance
The following infectious diseases are known to be active, such as:
Human immunodeficiency virus antibody (HIV-AB) positive; Hepatitis B surface antigen (HBsAg) positive and HBV-DNA exceeding the upper limit of normal value; Hepatitis C virus antibody (HCV-AB) positive and HCV RNA positive
- Other active infections requiring intravenous antibiotics within 7 days before administration;
- Use of potent CYP inducer 28 days before administration or within 5 half-lives of the drug, whichever is longer A guide or inhibitor;
- Had undergone a major surgical procedure within 28 days prior to drug administration or was expected to require a major procedure during the trial Surgery;
- Received the latest antitumor therapy (chemotherapy, targeted therapy, radiotherapy, immunotherapy, biological therapy) Therapy or endocrine therapy), less than 5 half-lives after or after the first administration of the drug Less than 28 days (whichever is longer). Had received the drug within 14 days before the first dose with definite resistance The effect of traditional Chinese medicine on tumor;
A history of serious cardiovascular and cerebrovascular diseases, including but not limited to:
uncontrolled hypertension (systolic blood pressure >160 mmHg or shu) after standard clinical treatment Tension >100 mmHg for more than 4 weeks); I have severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias that require clinical intervention, Degree II-III atrioventricular block, etc Patients with grade III-IV cardiac insufficiency according to New York Heart Association (NYHA) criteria Any arterial thromboembolic event, including but not limited to myocardial infarction, occurred within 6 months prior to dosing Plug, transient ischemic attack, unstable angina pectoris or other grade 3 or above cardiovascular and cerebrovascular disease Events; Any factor that increases the risk of prolonged QTc intervals or arrhythmias: e.g., heart failure, hypokalemia Haemaemia, congenital long QT syndrome, or the use of anything known to prolong the QT interval Concomitant drugs (see Appendix of the main text for details), except antibiotics used to prevent or treat infection;
- Parenchymal or meningeal metastases with clinical symptoms were not eligible for inclusion as judged by the investigator. Such as Previous systemic and radical brain metastases therapy (radiotherapy or surgery) proved stable on imaging It has been maintained for at least 28 days and has stopped systemic hormone therapy for more than 14 days without clinical symptoms Is allowed to enter the group;
- Suffers from hematological malignancies;
- Other malignant tumors have been diagnosed within 5 years before the first use of the study drug; Effectively treated skin Basal cell carcinoma, squamous cell carcinoma of the skin, and/or effectively resected cervical cancer in situ and/or breast Except the cancer;
- Inability to swallow medication;
- Gastrointestinal diseases that may affect the absorption or tolerability of the trial drug, such as refractory or screening CTCAE> grade 2 gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea, etc.);
- Patients with difficulty in venous blood collection;
- Women who have a positive pregnancy test or are breastfeeding during the screening period;
- Administration of an investigational drug that has undergone clinical trials of other drugs within 28 days prior to administration;
- Previous treatment with other Aurora kinase inhibitors;
- Patients with a history of blood donation or blood loss of more than 400 mL 3 months before screening;
- Anything else that, in the opinion of the investigator, may affect the subject to provide informed consent or follow the protocol Circumstances, or the subject's participation in the trial may affect the results of the trial or their own safety.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose escalation phase-Dose group 1 VIC-1911 Tablets with Osimertinib Mesylate Tablets
Advanced NSCLC patients who experienced first/second-generation EGFR-TKI failure with T790M mutation negative or who experienced third-generation EGFR-TKI failure and a subsequent platinum-based doublet chemotherapy failure
|
VIC-1911 tablets for oral administration
Osimertinib tablets for oral administration
Other Names:
|
Experimental: Dose escalation stage - Dose group 2 VIC-1911 Tablets with Osimertinib Mesylate Tablets
Advanced NSCLC patients who experienced first/second-generation EGFR-TKI failure with T790M mutation negative or who experienced third-generation EGFR-TKI failure and a subsequent platinum-based doublet chemotherapy failure
|
VIC-1911 tablets for oral administration
Osimertinib tablets for oral administration
Other Names:
|
Experimental: Dose expansion phase VIC-1911 Tablets with Osimertinib Mesylate Tablets
Cohort 1: NSCLC patients who experienced first/second-generation EGFR-TKI failure with T790M mutation positive; Cohort 2: NSCLC patients who experienced third-generation EGFR-TKI failure
|
VIC-1911 tablets for oral administration
Osimertinib tablets for oral administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment emergent adverse events (safety and tolerability)
Time Frame: 36 months
|
Safety and tolerability assessed by adverse events(AEs) and serious adverse events (SAEs)
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic PK parameters
Time Frame: C1D1 and C1D4 in the first period
|
Cmax
|
C1D1 and C1D4 in the first period
|
Time to Response
Time Frame: Assessed from the date of the first dose of study drug to the first evidence of disease progression or death, whichever is earlier,Expected to evaluate to 36month
|
Length of time from the date of first dose of study drug to the first evidence of objective response (CR,PR)
|
Assessed from the date of the first dose of study drug to the first evidence of disease progression or death, whichever is earlier,Expected to evaluate to 36month
|
Disease Control Rate
Time Frame: Assessed from the date of the first dose of study drug to the first evidence of disease progression or death, whichever is earlier,Expected to evaluate to 36month
|
Proportion of subjects with best response of CR, PR or stable disease (SD)
|
Assessed from the date of the first dose of study drug to the first evidence of disease progression or death, whichever is earlier,Expected to evaluate to 36month
|
Progression-Free Survival
Time Frame: Assessed from the date of the first dose of study drug to the first evidence of disease progression or death, whichever is earlier,Expected to evaluate to 36month
|
Length of time from the date of first dose of study drug to the first evidence of disease progression or death, whichever is earlier
|
Assessed from the date of the first dose of study drug to the first evidence of disease progression or death, whichever is earlier,Expected to evaluate to 36month
|
Overall Survival
Time Frame: Assessed from the date of the first dose of study drug to the first evidence of disease progression or death, whichever is earlier,Expected to evaluate to 36month
|
Length of time from the date of first dose of study drug to date of death from any cause
|
Assessed from the date of the first dose of study drug to the first evidence of disease progression or death, whichever is earlier,Expected to evaluate to 36month
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Osimertinib
Other Study ID Numbers
- JSI-1911-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Non-small Cell Lung Cancer
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerFrance, Korea, Republic of, United Kingdom, Spain
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerBelgium, United States, Korea, Republic of, Taiwan, United Kingdom, Netherlands
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerUnited States, France, Germany, Korea, Republic of, Taiwan, United Kingdom, Spain, Italy, Japan, Australia
-
Peking University First HospitalMerck Sharp & Dohme LLCNot yet recruitingAdvanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung CancerChina
-
Gradalis, Inc.WithdrawnLung Neoplasms | Advanced Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung CancerUnited States
-
Cancer Research UKBicycle TherapeuticsCompletedNon-Small Cell Lung Cancer | Advanced Solid Tumours | Oesophageal Cancer | Non-Small Cell Lung SarcomaUnited Kingdom
-
Mirati Therapeutics Inc.RecruitingAdvanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung CancerUnited States, Korea, Republic of, Italy, Spain, Czechia, Hungary, Netherlands, Canada, Australia, Austria, Belgium, Germany, Ireland, Israel, Poland, United Kingdom, Taiwan, Portugal
-
LianBio LLCRecruitingAdvanced Solid Tumor | Advanced or Metastatic Non-small Cell Lung CancerChina
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyCompletedNon-small Cell Lung Cancer | Advanced Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung CancerUnited States
Clinical Trials on VIC-1911
-
Masonic Cancer Center, University of MinnesotaRecruitingLymphoma | Myelodysplastic Syndromes | Acute Leukemia | Myeloproliferative NeoplasmUnited States
-
Vitrac Therapeutics, LLCWestatTerminatedNon-small Cell Lung CancerUnited States
-
Yale UniversityCompletedPatient Centered Outcomes ResearchUnited States
-
QuantumLeap Healthcare CollaborativeByondis B.V.WithdrawnOvarian Cancer | Metastatic Cancer | Metastatic Breast Cancer | Bladder Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Gastroesophageal Adenocarcinoma | Ovarian Carcinoma | HER2-positive Gastric Cancer | Metastatic Gastrointestinal Carcinoid Tumor | HER2-positive Metastatic Breast... and other conditionsUnited States
-
Byondis B.V.CompletedEndometrial CancerKorea, Republic of, Singapore, Russian Federation, Ukraine, United States, Poland, Serbia
-
Bioventus LLCCompletedOsteoarthritis of the Shoulder
-
Fudan UniversityRecruiting
-
Byondis B.V.CompletedSolid TumorUnited Kingdom, Belgium, Netherlands
-
Byondis B.V.CompletedMetastatic Breast CancerFrance, Belgium, Spain
-
Byondis B.V.CompletedMetastatic Breast CancerFrance, United States, United Kingdom, Belgium, Spain, Italy, Singapore, Denmark, Sweden, Canada, Netherlands